Cantor Fitzgerald Reaffirms “Overweight” Rating for Lucid Diagnostics (NASDAQ:LUCD)

Lucid Diagnostics (NASDAQ:LUCD)‘s stock had its “overweight” rating reiterated by stock analysts at Cantor Fitzgerald in a research note issued on Wednesday,Benzinga reports. They presently have a $2.00 target price on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 25.79% from the company’s previous close.

A number of other research firms have also weighed in on LUCD. Ascendiant Capital Markets dropped their target price on Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating on the stock in a report on Monday, December 9th. Needham & Company LLC upped their target price on shares of Lucid Diagnostics from $2.50 to $3.00 and gave the stock a “buy” rating in a research note on Monday. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Lucid Diagnostics currently has a consensus rating of “Buy” and an average price target of $3.40.

Lucid Diagnostics Price Performance

LUCD opened at $1.59 on Wednesday. Lucid Diagnostics has a fifty-two week low of $0.63 and a fifty-two week high of $1.63. The firm has a market capitalization of $94.35 million, a PE ratio of -1.39 and a beta of 1.34. The company’s 50-day moving average is $1.26 and its 200 day moving average is $1.00.

Institutional Investors Weigh In On Lucid Diagnostics

Hedge funds have recently made changes to their positions in the business. Sargent Investment Group LLC purchased a new stake in Lucid Diagnostics during the fourth quarter worth about $442,000. Citadel Advisors LLC purchased a new stake in shares of Lucid Diagnostics during the 4th quarter worth approximately $98,000. Sunbelt Securities Inc. bought a new stake in shares of Lucid Diagnostics in the 4th quarter worth approximately $67,000. Lido Advisors LLC lifted its stake in Lucid Diagnostics by 40.0% in the fourth quarter. Lido Advisors LLC now owns 140,016 shares of the company’s stock valued at $115,000 after purchasing an additional 40,000 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Lucid Diagnostics by 30.9% in the fourth quarter. Geode Capital Management LLC now owns 279,504 shares of the company’s stock worth $229,000 after buying an additional 65,964 shares during the last quarter. 74.01% of the stock is currently owned by institutional investors.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.